FDA Argues Summary Judgment Warranted In Mifepristone Restrictions Case
YAKIMA, Wash. — The U.S. Food and Drug Administration argues in a May 30 reply brief on its cross-motion for summary judgment filed in a Washington federal court that only the...To view the full article, register now.
Already a subscriber? Click here to view full article